Immunovant, Inc. (IMVT)
- Previous Close
29.76 - Open
29.91 - Bid 29.63 x 600
- Ask 29.73 x 100
- Day's Range
29.38 - 30.00 - 52 Week Range
17.53 - 45.58 - Volume
610,647 - Avg. Volume
1,144,204 - Market Cap (intraday)
4.315B - Beta (5Y Monthly) 0.75
- PE Ratio (TTM)
-- - EPS (TTM)
-1.81 - Earnings Date May 13, 2024 - May 27, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
50.86
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
immunovant.comRecent News: IMVT
Performance Overview: IMVT
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IMVT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IMVT
Valuation Measures
Market Cap
4.32B
Enterprise Value
3.63B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
6.36
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-14.34
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.15%
Return on Equity (ttm)
-44.51%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-243.45M
Diluted EPS (ttm)
-1.81
Balance Sheet and Cash Flow
Total Cash (mrq)
690.94M
Total Debt/Equity (mrq)
0.05%
Levered Free Cash Flow (ttm)
-125.81M
Research Analysis: IMVT
Company Insights: IMVT
IMVT does not have Company Insights